过敏性鼻炎采用氯雷他定与孟鲁司特治疗的临床效果及不良反应发生率分析

Analysis of clinical effect and incidence of adverse reactions of allergic rhinitis treated with loratadine and montelukast

目的体会氯雷他定联合孟鲁司特治疗过敏性鼻炎的临床价值。方法遵从药物差异分组原则,择我院2019.3-2020.4内的85例过敏性鼻炎患者分为对照组(43例,氯雷他定单纯治疗)和观察组(42例,氯雷他定联合孟鲁司特治疗),观察临床疗效及不良反应发生率。结果观察组临床疗效显著较对照组高(97.6%vs83.7%),不良反应发生率明显较对照组低(7.1%vs25.5%),P<0.05。结论对过敏性鼻炎患者实施药物治疗,建议以氯雷他定治疗为基准,而后联合孟鲁司开展治疗;在提升临床疗效、降低药物不良反应发生率方面具有显著价值。

Objective To understand the clinical value of loratadine combined with montelukast in the treatment of allergic rhinitis.Methods Following the principle of drug difference grouping,85 patients with allergic rhinitis within our hospital’s 2019.3-2020.4 were divided into a control group(43 cases,loratadine treatment alone)and an observation group(42 cases,loratadine combined with Meng Lusit treatment);observe the clinical efficacy and incidence of adverse reactions.Results The clinical efficacy of the observation group was significantly higher than that of the control group(97.6%vs 83.7%),and the incidence of adverse reactions was significantly lower than that of the control group(7.1%vs 25.5%),P<0.05.Conclusion For the treatment of patients with allergic rhinitis,it is recommended to take loratadine as the benchmark,and then carry out treatment with montelukast;it has significant value in improving clinical efficacy and reducing the incidence of adverse drug reactions.